Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 6/20 | 0.69 |
| ▸ | RXRB | P28702 | 6/20 | 0.69 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.62 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.59 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.59 |
| ▸ | RXRG | P48443 | 1/20 | 0.57 |
| ▸ | BCL2 | P10415 | 1/20 | 0.57 |
| ▸ | DCLRE1B | Q9H816 | 1/20 | 0.55 |
| ▸ | KMO | O15229 | 1/20 | 0.55 |
| ▸ | EGFR | P00533 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.54 |
| ▸ | PDE4A | P27815 | 1/20 | 0.53 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.53 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.53 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.53 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7827055 | 0.86 | RXRA (0.82) | RXRARXRBMAP4K4DCLRE1BKMO | |
| SCHEMBL10631530 | 0.86 | ALOX5 (0.55) | RXRARXRBMAP4K4DCLRE1BALOX5 | |
| SCHEMBL16166011 | 0.86 | KMO (0.72) | RXRARXRBTRIM24TRIM33RXRG | |
| SCHEMBL30066684 | 0.86 | KMO (0.72) | RXRARXRBTRIM24TRIM33RXRG | |
| SCHEMBL2346605 | 0.84 | KMO (0.76) | RXRARXRBTRIM24TRIM33RXRG | |
| SCHEMBL29906143 | 0.84 | KMO (0.76) | RXRARXRBTRIM24TRIM33RXRG | |
| SCHEMBL27607318 | 0.83 | TSHR (0.67) | RXRARXRBTRIM24TRIM33RXRG | |
| SCHEMBL10799811 | 0.83 | SMN1; SMN2 (0.62) | RXRARXRBALOX5TAAR1 | |
| SCHEMBL2690729 | 0.83 | NPC1 (0.64) | MAP4K4ALOX5TAAR1 | |
| SCHEMBL7553675 | 0.83 | RARA (0.58) | RXRARXRBMAP4K4EGFRPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7109243-B2 | Inhibitors of cathepsin S | IRM LLC (BM) | 2006-09-19 | — | — | US | claimed |
| US-5580741-A | INCUBATING SAMPLE SOLUTION IN CONTAINER PRECOATED WITH ANTIBODY AND PROTEIN CONJUGATE YIELDS COMPLEXES, THEN REMOVAL AND REACTION WITH CHEMILUMINESCENT REAGENTS FOR MEASUREMENT OF LIGHT INTENSITY, FOR CHLORINATED BIPHENYLS | GENERAL ELECTRIC COMPANY (US) | 1996-12-03 | — | — | US | claimed |
| US-20250179046-A1 | SEROTONIN 5-HT2B INHIBITORY COMPOUNDS | ZOETIS SERVICES LLC | 2025-06-05 | — | — | US | disclosed |
| US-12240827-B2 | Serotonin 5-HT2B inhibitory compounds | ZOETIS SERVICES LLC (US) | 2025-03-04 | — | — | US | disclosed |
| EP-3947360-B1 | SEROTONIN 5-HT2B INHIBITORY COMPOUNDS | ZOETIS SERVICES LLC (US) | 2024-08-07 | — | — | EP | disclosed |
| US-20220162183-A1 | SEROTONIN 5-HT2B INHIBITORY COMPOUNDS | ZOETIS SERVICES LLC | 2022-05-26 | — | — | US | disclosed |
| US-11299484-B2 | Inhibiting fatty acid synthase (FASN) | FORMA THERAPEUTICS, INC. (US) | 2022-04-12 | — | — | US | disclosed |
| US-11072582-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | EPICS THERAPEUTICS (BE) | 2021-07-27 | — | — | US | disclosed |
| US-20210024508-A1 | INHIBITING FATTY ACID SYNTHASE (FASN) | FORMA THERAPEUTICS, INC. | 2021-01-28 | — | — | US | disclosed |
| US-20200399282-A1 | INHIBITORS OF TRPC6 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-12-24 | — | — | US | disclosed |
| US-20200347016-A1 | SUBSTITUTED PYRROLIDINES AS G-PROTEIN COUPLED RECEPTOR 43 AGONISTS | EPICS THERAPEUTICS (BE) | 2020-11-05 | — | — | US | disclosed |
| EP-1268418-A1 | PHARMACEUTICALLY ACTIVE PYRROLIDINE DERIVATIVES AS BAX INHIBITORS | Applied Research Systems ARS Holding N.V. (AN) | 2003-01-02 | — | — | EP | disclosed |
| WO-2002102799-A2 | PYRROLIDINE OXADIAZOLE- AND THIADIAZOLE OXIME DERIVATIVES BEING OXYTOCIN RECEPTOR ANTAGONISTS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2002-12-27 | — | — | WO | disclosed |
| WO-2002074741-A1 | PYRROLIDINE ESTER DERIVATIVES WITH OXYTOCIN MODULATING ACITVITY | APPLIED RESEARCH SYSTEMS ARS HOLDING NV (AN) | 2002-09-26 | — | — | WO | disclosed |
| US-20020086887-A1 | N-Acylsulfonamide apoptosis promoters | ABBVIE INC. | 2002-07-04 | — | — | US | disclosed |
| US-20020055631-A1 | N-acylsulfonamide apoptosis promoters | ABBOTT LABORATORIES | 2002-05-09 | — | — | US | disclosed |
| WO-2001074769-A1 | PHARMACEUTICALLY ACTIVE PYRROLIDINE DERIVATIVES AS BAX INHIBITORS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2001-10-11 | — | — | WO | disclosed |
| WO-2001072705-A1 | PHARMACEUTICALLY ACTIVE PYRROLIDINE DERIVATIVES AS BAX INHIBITORS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2001-10-04 | — | — | WO | disclosed |
| WO-2001064213-A1 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-09-07 | — | — | WO | disclosed |
| US-4578522-A | CHEMICAL INTERMEDIATES FOR BLOOD LIPID CONTROLLING COMPOUNDS | BURROUGHS WELLCOME CO. | 1986-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12240827-B2 | Serotonin 5-HT2B inhibitory compounds | HTR2B, HTR1B, HTR5A | RXRA 3714/4885RXRB 2415/4885MAP4K4 2347/4885 |
| US-20020086887-A1 | N-Acylsulfonamide apoptosis promoters | BAX, BCLAF1, BCL2 | RXRA 2726/4885RXRB 2152/4885MAP4K4 3636/4885 |
| US-20220162183-A1 | SEROTONIN 5-HT2B INHIBITORY COMPOUNDS | HTR2B, HTR1B, HTR5A | RXRA 3714/4885RXRB 2415/4885MAP4K4 2347/4885 |
| US-20200399282-A1 | INHIBITORS OF TRPC6 | TRPC6, TRPC1, TRPC4 | RXRA 2572/4885RXRB 2721/4885MAP4K4 1609/4885 |
| US-20250179046-A1 | SEROTONIN 5-HT2B INHIBITORY COMPOUNDS | HTR2B, HTR1B, HTR5A | RXRA 3714/4885RXRB 2415/4885MAP4K4 2347/4885 |
| US-20020055631-A1 | N-acylsulfonamide apoptosis promoters | BAX, BCLAF1, BCL2 | RXRA 3190/4885RXRB 2453/4885MAP4K4 3771/4885 |
| US-20200347016-A1 | SUBSTITUTED PYRROLIDINES AS G-PROTEIN COUPLED RECEPTOR 43 AGONISTS | GPR119, GPR52, GPR88 | RXRA 780/4885RXRB 573/4885MAP4K4 1516/4885 |
| US-20210024508-A1 | INHIBITING FATTY ACID SYNTHASE (FASN) | FASN, SCD, FADS1 | RXRA 659/4885RXRB 590/4885MAP4K4 2810/4885 |
| US-11072582-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | GPR119, GPR52, GPR88 | RXRA 780/4885RXRB 573/4885MAP4K4 1516/4885 |
| US-11299484-B2 | Inhibiting fatty acid synthase (FASN) | FASN, SCD, FADS1 | RXRA 659/4885RXRB 590/4885MAP4K4 2810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.